Abstract: A method of producing a particle cassette for a needleless syringe device which alleviates problems of providing a chamber for the confinement of particles which is hermetically sealed from the environment. A predetermined force is applied in the longitudinal direction to push first and second cassette parts together so as to cause plastic deformation of a portion of the first cassette part so as to create said hermetically sealed chamber. The cassette parts are preferably made of PETG and have bonded thereto rupturable membranes preferably made of PET. The sealing is preferably achieved at the end of a protrusion on the first cassette part which is tapered and which interacts with the membrane of the second cassette part.
Type:
Grant
Filed:
June 4, 2007
Date of Patent:
October 30, 2012
Inventors:
Nigel Robert Bates, Philip Thomas Price, John Watson, Stuart Graham Weekes
Abstract: Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.
Type:
Grant
Filed:
October 19, 2010
Date of Patent:
April 19, 2011
Assignee:
Serenex, Inc.
Inventors:
Kenneth He Huang, Jeron Eaves, Gunnar Hanson, James Veal, Thomas Barta, Lifeng Geng, Lindsay Hinkley
Abstract: The present invention relates to methods for preparing indazole compounds of formula I, which are useful as modulators and/or inhibitors of protein kinases. The present invention also relates to intermediate compounds useful in the preparation of compounds of formula I.
Type:
Grant
Filed:
October 31, 2005
Date of Patent:
June 19, 2007
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Brigitte Leigh Ewanicki, Erik Jon Flahive, Annie Judith Kasparian, Mark Bryan Mitchell, Michael David Perry, Stacy Ann O'Neill-Slawecki, Neal William Sach, James Edward Saenz, Bing Shi, Nebojsa Slobodan Stankovic, Jayaram Kasturi Srirangam, Qingping Tian, Shu Yu
Abstract: The invention relates to compounds represented by Formula (I): and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein each of X1–X5 and R1–R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
Type:
Grant
Filed:
August 26, 2004
Date of Patent:
April 24, 2007
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Jihong Lou, Robert Steven Kania, Mingying He
Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Type:
Grant
Filed:
August 12, 2003
Date of Patent:
November 28, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Steven Bender, Dana Hu-Lowe, David Ray Shalinsky
Abstract: The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the ???3 and/or the ???5 integrin without significantly antagonizing the IIb/IIIa integrin.
Type:
Grant
Filed:
June 15, 2001
Date of Patent:
October 10, 2006
Assignee:
Pharmacia Corporation
Inventors:
Srinivasan Raj Nagarajan, Ish Kumar Khanna, Michael B. Tollefson, Scott B. Mohler, Barbara B. Chen, Mark Russell, Balekudru Devadas, Thomas D. Penning, Lori A. Schretzman, Dale P. Spangler, Mark L. Boys, Nizal S. Chandrakumar, Hwang-Fun Lu
Abstract: The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the ?v?3 and/or the ?v?5 integrin without significantly inhibiting the ?v?6 integrin.
Type:
Grant
Filed:
December 19, 2003
Date of Patent:
October 3, 2006
Assignee:
Pharmacia Corporation
Inventors:
John A. Wendt, Heather Stenmark, Hongwei Wu, Yaping Wang, Barbara B. Chen, Thomas D. Penning, Victoria L. Downs, Mark L. Boys, Mark Russell, Dale P. Spangler
Abstract: The present invention relates to a class of compounds represented by the formula (I) or a pharmaceutical acceptable salt, prodrug or ester thereof, pharmaceutical compositions comprising compounds of the formula (I), and methods of selectively inhibiting or antagonizing ?v?3 integrin.
Abstract: The invention relates to compounds of the formulas 1 and 2 and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
February 7, 2006
Assignee:
Agouron Pharmaceuticals, Inc.
Inventors:
Christopher Autry, Michael J. Luzzio, Matthew A. Marx